Orexo AB (ORX) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Orexo Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.196 Welcome to the conference call. For the first part of the conference call, the participants 00:00:04.196 -- 00:00:08.520 will be in listen-only mode. During the questions and answer session, participants are 00:00:08.520 -- 00:00:13.466 able to ask questions by dialing star 5 on their telephone keypad. 00:00:13.466 -- 00:00:15.928 Now I will hand the conference over to the speakers. 00:00:15.928 -- 00:00:18.269 Please go ahead. 00:00:19.192 -- 00:00:23.457 Thank you very much, and welcome to this third quarter call for Rexo. 00:00:23.457 -- 00:00:27.822 It has indeed been a transformative quarter in many ways for the company, in particular 00:00:27.822 -- 00:00:32.946 in our R&D departments where we have made very good progress in two 00:00:32.946 -- 00:00:35.229 projects, and I will come back to that a little later. 00:00:35.229 -- 00:00:37.229 Today, 00:00:37.933 -- 00:00:42.999 I'm Nicolai Sorensen, and I will be joined by Fredrik Gerstein, our CFO, 00:00:42.999 -- 00:00:47.806 and this time also Ed Kim, our chief medical officer, who I believe will be new to many 00:00:47.806 -- 00:00:53.333 of you, but Ed Kim will talk a little bit more about our OEC 390 project 00:00:53.333 -- 00:00:59.465 and why we think this is an important project both for Oryxo, but also for the U.S. 00:00:59.465 -- 00:01:04.210 We will go through the business update. I will take that, and as I said, it will come 00:01:04.210 -- 00:01:08.595 in on the products under development, focusing on OECD 390. 00:01:08.595 -- 00:01:13.040 Frederik will take us through the financials before I will close out with the legal update 00:01:13.040 -- 00:01:18.205 and some approach for expansion for where we think we have some future value 00:01:18.205 -- 00:01:20.205 dri...